Trial Profile
An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren/valsartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms ViVID
- 22 May 2012 Results presented at the 27th Annual Scientific Meeting of the American Society of Hypertension.
- 03 May 2012 Actual patient number 998 added as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.